Cell culture-derived influenza vaccines

Birkhauser Advances in Infectious Diseases

Volumn , Issue , 2011, Pages 293-312

  Dormitzer, Philip R ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INFLUVAC TC; LIVE VACCINE; OVALBUMIN; OVOMUCOID; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ARTICLE; AVIAN INFLUENZA VIRUS; BIOSAFETY; CELL CULTURE; CELL STRAIN; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; EGG; EGG ALLERGY; FEVER; GENETIC REASSORTMENT; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MAMMAL CELL; NONHUMAN; PANDEMIC INFLUENZA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STRAIN DIFFERENCE; VERO CELL; VIRUS GENOME; VIRUS ISOLATION; VIRUS STRAIN; VIRUS VIRULENCE;

EID: 79960073261     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0279-2_12     Document Type: Article

References (82)

1. Oxford J, Lambkin-Williams W, Gilbert A (2008) Influenza vaccines have a short but illustrious history. In: Rappuoli R, Del Giudice G (eds) Influenza vaccines for the future. Birkhaeuser, Basel, pp 31-64
2. Nicolson C, Major D, Wood JM, Robertson JS (2005) Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23:2943-2952
3. Burnet FM (1941) Growth of influenza virus in the allantoic cavity of the chick embryo. Aust J Exp Biol Med Sci 19:291-295
4. Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett CD Jr, Lease GO (1964) Comparisons of serological and febrile responses in humans to vaccination with influenza viruses or their hemagglutinins. J Lab Clin Med 63:5-13
5. Alexandrova GI, Smorodintsev AA (1965) Obtaining of an additionally attenuated vaccinating cryophilic influenza strain. Roum Rev Inframicrobiol 2:179
6. Reimer CB, Baker RS, Van Frank RM, Newlin TE, Cline GB, Anderson NG (1967) Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1: 1207-1216
7. Kilbourne ED (1969) Future influenza vaccines and use of genetic recombinants. Bull WHO 41:643-645
8. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56:152-179
9. Connor RJ, Kawaoka Y, Webster RG, Paulson JC (1994) Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205:17-23
10. Shibya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Avian flu: influenza virus receptors in the human airways. Nature 440:435-436
11. Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, Raguram S, Tumpey TM, Sasisekharan V, Sasisekharan R (2008) Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol 26:107-113
12. Eisen MB, Sabesan S, Skehel JJ, Wiley DC (1997) Binding of the influenza A virus to cellsurface receptors: sstructures of five hemagglutinin-sialyloligosaccharide complexes determined by X-ray crystallography. Virology 232:19-31
13. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC (1983) Single amino acid substitutions in influenza hemagglutinin change receptor binding specificity. Nature 304:76-78
14. Ito T, Sizuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, Yamada M, Suzuki T, Kida H, Kawaoka Y (1997) Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 71:3357-3363
15. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza hemagglutinin and their involvement in antigenic variation. Nature 289:373-378
16. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69:531-569
17. Knossow M, Gaudier M, Douglas A, Barrére B, Bizebard T, Barbey C, Gigant B, Skehel JJ (2002) Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302:294-298
18. Robertson JS, Nicolson C, Major D, Robertson EW, Wood JM (1993) The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol 74:2047-2051
19. Schild GC, Oxford JS, de Jong JC (1983) Evidence of host-cell selection of influenza virus antigenic variants. Nature 303:706-709
20. Katz JM, Wang M, Webster RG (1990) Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 64:1808-1811
21. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild GC (1985) Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143:166-174
22. Katz JM, Naeve CW, Webster RG (1987) Host cell-mediated variation in H3N2 influenza viruses. Virology 156:386-395
23. Mastrosovich M, Mastrosovich T, Carr J, Roberts NA, Klenk HD (2003) Overexpression of the alpha-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase. J Virol 77:8418-8425
24. Oh DY, Barr IG, Mosse JA, Laurie KL (2008) MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 46:2189-2194
25. Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, Fabry L, Heldens JG, Kino Y, Kistner O, Kompier R, Makizumi K, Medema J, Mimori S, Ryan D, Schwarz R, Smith JS, Sugawara K, Trusheim H, Tsai TF, Krause R (2009) Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 27:2907-2913
26. Widjaja L, Ilyushina N, Webster RG, Webby RJ (2006) Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 350:137-145
27. CDC (2004) Preliminary assessment of the effectiveness of the 2003-2004 inactivated influenza vaccine - Colorado, December 2003. MMWR Morb Mortal Wkly Rep 53:8-11
28. CDC (2004) Update: influenza-associated deaths reported among children aged <18 years - United States, 2003-2004 influenza season. MMWR Morb Mortal Wkly Rep 52:1286-1288
29. Katz JM, Webster RG (1989) Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 160:191-198
30. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull World Health Org 73: 431-435
31. Maassab HF (1969) Biological and immunologic characteristics of cold-adapted influenza virus. J Immunol 102:728-732
32. Watanabe T, Watanabe S, Shinya K, Kim JH, Hatta M, Kawaoka Y (2009) Viral RNA polymerase complex promotes optimal growth of 1918 virus in the lower respiratory tract of ferrets. Proc Natl Acad Sci USA 106:588-592
33. Grimm D, Staeheli P, Hufbauer M, Koemer I, Martinez-Sobrido L, Solorzano A, Garcia-Sastre A, Haller O, Kochs G (2007) Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc Natl Acad Sci USA 104:6806-6811
34. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, Garcia-Sastre A, Palese P (2000) Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci USA 97:4309-4314
35. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeffmayer D, Kundl M, Popow-Kraupp T, Redberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipetl J, Dick-Gudenus R, Muster T (2010) A novel type of influenza vaccine: safety and immunogenicity of replicationdeficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis 201:354-362
36. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, Palese P, Muster T (1998) Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252:324-330
37. Shah K, Nathanson N (1976) Human exposure to SV40: review and comment. Am J Epidemiol 103:1-12
38. Stratton K, Almario DA, McCormick M (eds) (2002) Institute of medicine report. Immunization safety review: SV40 contamination of poliovaccine and cancer. The National Academy of Sciences, Washington, DC
39. Miyazawa T (2010) Endogenous retroviruses as potential hazards for vaccines. Biologicals. doi:10.1016j
40. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (2010) Guidance for industry. Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. Office of Communication, Outreach, and Development, Rockville, MD
41. Gregersen JP (2008) A risk assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine 26:3297-3304
42. Scholtissek C, Stech J, Krauss S, Webster RG (2002) Cooperation between the emagglutinin of avian viruses and the matrix protein of human influenza A viruses. J Virol 76:1781-1786
43. Wood JM, Robertson JS (2004) From lethal to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2:842-847
44. Smith HO, Hutchison CA, Pfannkoch C, Venter JC (2003) Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. Proc Natl Acad Sci USA 100:15440-15445
45. Patriarca P (2007) Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations. IVR/WHO report, Geneva, Switzerland
46. Genzel Y, Reichel U (2009) Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 8:1681-1692
47. Tripp RA, Tompkins SM (2008) Recombinant vaccines for influenza virus. Curr Opin Investig Drugs 9:836-845
48. Doroshenko A, Halperin S (2009) Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis vaccines). Expert Rev Vaccines 8:679-688
49. Barrett PN, Mundt W, Kistner O, Howard MK (2009) Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8:607-618
50. Levenbook IS, Petricciani JC, Elisberg BL (1984) Tumorigenicity of Vero cells. J Biol Stand 12:391-398
51. Shin SI, Freedman VH, Risser R, Pollack R (1975) Tumorigenicity of virus-transformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci USA 72:4435-4439
52. Keenan J, Pearson D, Clynes M (2006) The role of recombinant proteins in the development of serum-free media. Cytotechnology 50:49-56
53. Schulze-Horsel J, Schulze M, Agalaridis G, Genzal U, Reichl U (2009) Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production - flow cytometry and mathematical modeling. Vaccine 27:2712-2722
54. Centers for Disease Control and Prevention (CDC) (2004) Updated interim influenza vaccination recommendations - 2004-05 influenza season. MMWR Morb Mortal Wkly Rep 53:1183-1184
55. Chiron (2005) Use of MDCK cells for the manufacture of inactivated influenza virus vaccines. VRBPAC 16 Nov 05 meeting. Available from http://www.fda.gov/ohrms/dockets/ac/05/slides/5-4188S1_5.pdf
56. Petricciani JC, Regan PJ (1987) Risk of neoplastic transformation from cellular DNA: calculations using the oncogene model. Dev Biol Stand 68:43-49
57. Morgeaux S, Tordo N, Gontier C, Perrin P (1993) Beta-propiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus. Vaccine 11:82-90
58. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F (2001) The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19:2716-2721
59. Rous P (1911) A sarcoma of the fowl transmissible by an agent separable from the tumor cell. J Exp Med 13:397-411
60. Stehelin D, Varmus HE, Bishop JM, Vogt PK (1976) DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260:170-173
61. Schild GC, Wood JM, Newman RW (1975) A single radial immunodiffusion technique for the assay of haemagglutinin antigen. WHO Bull 52:223-231
62. Wood JM, Dunleavy U, Newman RW, Riley AM, Robertson JS, Minor PD (1999) The influence of the host cell on standardization of influenza vaccine potency. Dev Biol Stand 98:183-188
63. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A (2009) Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 200:841-848
64. Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF (2010) Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28:840-848
65. Ehrlich HJ, Muller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pollabauer EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. New Engl J Med 358:2573-2584
66. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. New Engl J Med 361:2424-2435
67. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ (2009) Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety reactogenicity, and immunogenicity. J Infect Dis 200:849-857
68. Kistner O, Barrett PN, Mundt W, Schober-Bendixen S, Dorner F (1998) Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16:960-968
69. Halperin SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T, Treanor J, Gauthier R, Mills EL (2002) Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20:1240-1247
70. Palache AM, Scheepers HSJ, de Regt V, van Ewijk P, Baljet M, Brands R, van Scharrenburg GJM (1999) Safety, reactogenicity, and immunogenicity of Madin Darby canine kidney cellderived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev Biol Stand 98:115-125
71. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A (2009) Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential phase I and phase II clinical trial. Vaccine 27:786-791
72. Palache AM, Brands R, van Scharrenburg GJ (1997) Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 176(Suppl 1):S20-S23
73. Halperin SA, Nestruck AC, Eastwood BJ (1998) Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 16:1331-1335
74. Ehrlich HJ, Muller M, Fritsch S, Zeitlinger M, Berezuk G, Low-Baselli A, van der Velden MV, Pollbauer EM, Martisch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P (2009) A cell culture (Vero)-derived H5N1 whole-virus vaccine induces crossreactive memory responses. J Infect Dis 200:1113-1138
75. Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, Kong WP, Yang ZY, Tumpey TM, Nabel GJ (2010) Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 24:24ra21
76. Scharzer J, Rapp E, Hennig R, Genzel Y, Jordan I, Sandig V, Reichl U (2009) Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine 27:4325-4336
77. Tey D, Heine RG (2009) Egg allergy in childhood: an update. Curr Opin Allergy Clin Immunol 9:244-250
78. Tubiolo VC, Beall GN (1997) Dog allergy: understanding our 'best friend'? Clin Exp Allergy 27:354-357
79. Wanich N, Bencharitiwong R, Tsai T, Nowak-Wegrzyn AH (2009) In vitro assessment of the allergenicity of novel influenza vaccine produced in dog kidney cells in subjects with dog allergy. J Allergy Clin Immunol 123:S114
80. Ronmark E, Perzanowski M, Platts-Mills T, Lundback B (2003) Four-year incidence of allergic sensitization among schoolchildren in a community where allergy to cat and dog dominates sensitization: Report from the Obstructive Lung Disease in Northern Sweden Study Group. J Allergy Clin Immunol 112:747-754
81. Novartis Media Releases (2009) US Department of Health and Human Services awards Novartis USD 486 million contract to build manufacturing facility for pandemic flu vaccine. http://www.novartis.com/newsroom/media-releases/en/2009/1282432.shtml
82. Kock M, Seemann G (2008) Fertile eggs - a valuable product for vaccine production. Lohmann Inf 43:37-40